Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Grande

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
Immunologic Research|December 15, 2015
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activityRicardo García-Muñoz, Ascensión López-Díaz-de-Cerio, Jesus Feliu, et al.
Medicina Clinica|January 20, 2012
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]Miguel Ángel Sanz, Vicente Vicente García, Antonio Fernández, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2016
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO TrialMonica Cabrero, Alejandro Martin, Javier Briones, et al.
Cancer|May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesHagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Journal of Clinical Microbiology|December 26, 2008
Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropeniaManuel Cuenca-Estrella, Yolanda Meije, Carmen Diaz-Pedroche, et al.
Cancer|June 12, 2009
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomasCristina Robledo, Juan L García, Dolores Caballero, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|January 24, 2021
The <sup>18</sup>F phantom clinical trials qualification for <sup>18</sup>F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)Fabrizio Bergesio, Adriano De Maggi, Mónica Coronado, et al.
Leukemia & Lymphoma|April 18, 2009
Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphomaAna I Saez, Mónica García-Cosío, Antonio J Sáez, et al.
European Journal of Haematology|December 20, 2007
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study GroupReyes Arranz, Eulogio Conde, Carlos Grande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96Josep-María Ribera, Albert Oriol, Miguel-Angel Sanz, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Immunologic Research|December 15, 2015
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activityRicardo García-Muñoz, Ascensión López-Díaz-de-Cerio, Jesus Feliu, et al.
Medicina Clinica|January 20, 2012
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]Miguel Ángel Sanz, Vicente Vicente García, Antonio Fernández, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2016
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO TrialMonica Cabrero, Alejandro Martin, Javier Briones, et al.
Cancer|May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesHagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Journal of Clinical Microbiology|December 26, 2008
Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropeniaManuel Cuenca-Estrella, Yolanda Meije, Carmen Diaz-Pedroche, et al.
Cancer|June 12, 2009
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomasCristina Robledo, Juan L García, Dolores Caballero, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|January 24, 2021
The <sup>18</sup>F phantom clinical trials qualification for <sup>18</sup>F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)Fabrizio Bergesio, Adriano De Maggi, Mónica Coronado, et al.
Leukemia & Lymphoma|April 18, 2009
Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphomaAna I Saez, Mónica García-Cosío, Antonio J Sáez, et al.
European Journal of Haematology|December 20, 2007
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study GroupReyes Arranz, Eulogio Conde, Carlos Grande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96Josep-María Ribera, Albert Oriol, Miguel-Angel Sanz, et al.
Pageof 10